Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

4,016 public trials 394 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

NCT01313637

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Long Beach, California, United States
  • GSK Investigational Site Los Angeles, California, United States
View all 157 locations
View Trial Details
Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Clearwater, Florida, United States
  • GSK Investigational Site Ormond Beach, Florida, United States
  • GSK Investigational Site Lafayette, Indiana, United States
View all 73 locations
View Trial Details
Completed

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

NCT01899742

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Medford, Oregon, United States
  • GSK Investigational Site Greenville, South Carolina, United States
  • GSK Investigational Site Spartanburg, South Carolina, United States
  • GSK Investigational Site La Plata, Buenos Aires, Argentina
View all 64 locations
View Trial Details
Completed

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02105974

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Riverside, California, United States
  • GSK Investigational Site Sunset, Louisiana, United States
  • GSK Investigational Site Saint Charles, Missouri, United States
  • GSK Investigational Site Charlotte, North Carolina, United States
View all 237 locations
View Trial Details
Completed

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

NCT01316900

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site San Diego, California, United States
  • GSK Investigational Site DeLand, Florida, United States
  • GSK Investigational Site Orlando, Florida, United States
View all 97 locations
View Trial Details
Completed

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

NCT02207829

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Spartanburg, South Carolina, United States
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Buenos Aires, Argentina
  • GSK Investigational Site Winnipeg, Manitoba, Canada
View all 99 locations
View Trial Details
Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01054885

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Jasper, Alabama, United States
  • GSK Investigational Site Lakewood, California, United States
  • GSK Investigational Site Long Beach, California, United States
View all 149 locations
View Trial Details
Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

NCT01777334

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Riverside, California, United States
  • GSK Investigational Site San Diego, California, United States
  • GSK Investigational Site DeLand, Florida, United States
View all 70 locations
View Trial Details
Completed

Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

NCT03256552

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease, Disease Attributes, +6 more
Locations
  • Pearl Investigative Site Fukuoka, Japan
  • Pearl Investigative Site Iizuka-shi, Fukuoka, Japan
  • Pearl Investigative Site Mizunami-shi, Gifu, Japan
  • Pearl Investigative Site Sapporo, Hokkaido, Japan
View all 18 locations
View Trial Details

Related conditions